Imidazopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
申请人:Heinelt Uwe
公开号:US08598177B2
公开(公告)日:2013-12-03
The invention relates to novel compounds of formula I
where R1, R2, R3, R4, R5, R6, R7, R8, R9, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
IMIDAZOPYRIDAZINE ALS PAR1-INHIBITOREN, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL
申请人:Sanofi-Aventis
公开号:EP2240179A2
公开(公告)日:2010-10-20
US8598177B2
申请人:——
公开号:US8598177B2
公开(公告)日:2013-12-03
[DE] IMIDAZOPYRIDAZINE ALS PAR1-INHIBITOREN, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] IMIDAZOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS<br/>[FR] IMIDAZOPYRIDAZINES EN TANT QU'INHIBITEURS DE PAR1, LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
申请人:SANOFI AVENTIS
公开号:WO2009097973A2
公开(公告)日:2009-08-13
Die Erfindung betrifft Verbindungen der Formel (I) mit antithrombotischer Aktivität, die insbesondere den Protease-aktivierten Rezeptor 1 (PAR1) inhibieren, Verfahren zu ihrer Herstellung und Verwendung derselben als Arzneimittel.
IMIDAZOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
申请人:HEINELT Uwe
公开号:US20110034456A1
公开(公告)日:2011-02-10
The invention relates to novel compounds of formula I
where R1, R2, R3, R4, R5, R6, R7, R8, R9, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.